Navigation Links
ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
Date:4/30/2008

her, the higher concentration of Bepreve demonstrated a once-daily clinical effect that was comparable to the published literature for FDA-approved once-daily ophthalmic solutions studied in patients with ocular allergies.

The data announced today mirror the results from the 107-patient, single- center Phase III Bepreve study, announced May 8, 2007, which used the same study design. ISTA currently is analyzing the results of an ocular safety study in approximately 850 patients, with preliminary results anticipated before the end of the second quarter of 2008. Once the Company completes its analysis of the full dataset, ISTA expects to file a New Drug Application (NDA) with the FDA during the second half of 2008. ISTA plans to discuss the study results with the FDA to determine what, if any, additional information would be required in order to obtain approval for both a once-daily and twice- daily form of Bepreve.

About Bepreve(TM) (bepotastine ophthalmic solution)

Bepreve has three primary mechanisms of action: it is a non-sedating, highly selective antagonist of the histamine 1 (H1) receptor, it has a stabilizing effect on mast cells, and it suppresses the migration of eosinophils into inflamed tissues. The compound's primary mechanisms of action are believed to make it an effective treatment against the signs and symptoms of allergic conjunctivitis.

Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju Pharmaceutical Co., Ltd., exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture, and market bepotastine for ophthalmic use. In 2
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
2. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
3. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
6. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
7. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
8. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
9. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Calif. , July 24, 2014  IRIDEX Corporation ... will release its second quarter 2014 financial results after ... In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, ... the quarter and other business developments. Interested ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
(Date:7/24/2014)... (NYSE MKT: IG), a New Jersey based specialty generic drug ... second quarter ended June 30, 2014. Second Quarter ... in the second quarter of 2014, an increase of 70% ... of $13.3 million for the six months ended June 30, ... 2013 , Total revenues generated from the sale of ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... Control, WASHINGTON, Jan. 10 To help ... risks during times,of health crisis, DuPont (NYSE: ... products, DuPont(TM) Corian(R) solid surface, has been selected,by ... The product,recently was incorporated into a children,s ward ...
... South Korea, Jan. 10 Celltrion, Inc., a ... and CSL Limited, Australia,s leading biopharmaceutical,company, announced today ... supply of CSL 360, an experimental monoclonal antibody ... Phase I clinical trials for CSL,360 are currently ...
Cached Medicine Technology:DuPont Provides Technology for Washington Hospital Center's Emergency Department 2DuPont Provides Technology for Washington Hospital Center's Emergency Department 3DuPont Provides Technology for Washington Hospital Center's Emergency Department 4Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody 2
(Date:7/25/2014)... Gerontological Society of America (GSA) the ... of aging has chosen Heather M. Young, ... Davis, as the 2014 recipient of the Doris ... honor, presented by GSA,s Health Sciences Section, is ... recognition of outstanding and sustained contribution to gerontological ...
(Date:7/25/2014)... As reported by Wood TV 8 in the ... has seen a nearly 500-person increase in heroin related overdose ... 271 between 1999 and 2002, the toll increased to 728 ... other states, drug users in Michigan have turned to heroin ... compared the price of both substances, noting that an 80-milligram ...
(Date:7/25/2014)... As reported by People Magazine in the article Mike ... Sober (7/15), one of the most popular cast stars ... the public about his personal transformation. Now, two years later ... moving on with his life was a challenge. He was ... 2012 and even spent some time in rehab. He took ...
(Date:7/25/2014)... 25, 2014 The Little Gym of ... on Sunday, July 27 at Discovery Green in downtown ... Copperfield, Katy, Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, ... , “We’re thrilled to be attending and performing ... Belcher who owns the Sugarland-Missouri City location. “We believe ...
(Date:7/25/2014)... US (PRWEB) July 25, 2014 ... provider of technology-enabled services for the financial, legal, ... its virtual data room business, Merrill DataSite, has ... Year” presented by GrowthBusiness at the M&A Awards ... recognize the achievements of entrepreneurs, management teams, advisors ...
Breaking Medicine News(10 mins):Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2
... ... Mom’s site, and National Masturbation Month, Good Vibrations ,Celebrates Spring Fever , ... (PRWEB) -- Good Vibrations, the legendary San ... is proud to announce a fun and sexy new resource for moms at goodvibessexymama.com where ...
... ... ability to digitally sign documents online. , ... (PRWEB) May 13, 2010 -- Secured Signing, a web ... sign documents online with trusted, legally binding signatures. Businesses signing documents online reduce costs, ...
... Non surgical procedure restores the ... ... revolutionary hair replication solution recently at their Edina, Mn, office. They utilize a new process ... restores the permanent look of a full head of hair in one day and develops confidence ...
... The joint ... C.V. to provide a consistent supply of logwood extract used in the production of hematoxylin ... smear tests and hematine is used to dye medical sutures. Abbey Color is the world’s ... ...
... ... tumor surgeon, has been named as one of New York,s "Super Doctors" , ... New York, NY (PRWEB) May 12, 2010 For the ... "New York Super Doctor" in a special section of New York Magazine. As one of ...
... ... 12 of their Premier Literacy Suite of software literacy tools. , ... (PRWEB) May 13, 2010 -- Kenneth Grisham, ... innovation to the field of literacy technology. Our reputation is built on creating robust ...
Cached Medicine News:Health News:Three Ways to Put A Spring In Your Step This Month With Good Vibrations 2Health News:Three Ways to Put A Spring In Your Step This Month With Good Vibrations 3Health News:Signing Documents Online, Now Available for Telecom NZ Business Hub Customers 2Health News:Good Look Ink Announces Revolutionary Hair Replication Solution 2Health News:Abbey Color Inc. and Mexicana de Extractos International, S.A. de C.V. Announce Joint Venture Abbymex 2Health News:Abbey Color Inc. and Mexicana de Extractos International, S.A. de C.V. Announce Joint Venture Abbymex 3Health News:Manhattan Orthopaedic Oncologist named as "Super Doctor" for 2010 in the New York Times Magazine 2Health News:Manhattan Orthopaedic Oncologist named as "Super Doctor" for 2010 in the New York Times Magazine 3Health News:Premier Literacy Releases Version 12 of the Most Comprehensive Offering of Literacy Tools Available Today 2Health News:Premier Literacy Releases Version 12 of the Most Comprehensive Offering of Literacy Tools Available Today 3
... In vitro diagnostic reagents for ... (CRP) in human serum as well ... means of particle-enhanced Immunonephelometry using the ... increased levels of a number of ...
Peapod Rongeur, 5.5 length 140 mm....
Suitable for children and adults. New mechanical design of the skull pin holder and the clamp base ensures improved rigid skull fixation....
The Skull Pins are inserted into the receptacles of the Skull Clamp and fixate the head during surgery....
Medicine Products: